Journals / Gülhane Tıp Dergisi / 2002 / Cilt: 44 - Sayı: 4

Cardiac troponin T, CK-MB, myoglobine levels in congestive heart failure

Konjestif kalp yetmezliğinde kardiyak troponin T, CK-MB, myoglobin düzeyleri

Pages
405–408
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The ejection fraction mean value was 30 ± 7% in patients group and 65 ± 5% in control group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Between January 2001 to June 2002 we prospectively examined 40 consecutive patients with congestive heart failure in our cardiology clinic.
📊
Key Findings & Data:Patients group consisted of 34 men and 6 women.
💡
Conclusion & Impact:The ejection fraction mean value was 30 ± 7% in patients group and 65 ± 5% in control group.
🔬Design:Research Article
📍Scope:2001 Verileri
⚙️Variables:İleriye dönük çalışma · Kreatin kinaz · Kalp yetmezliği

Abstract

Between January 2001 to June 2002 we prospectively examined 40 consecutive patients with congestive heart failure in our cardiology clinic. Patients with a history of recent myocardial infarction or symptomatic ischemia were excluded. Cardiac troponin T, CK - MB, myoglobine were measured using an immunoassay method. The severity of heart failure was evaluated by determining the New York Heart Association functional class. Ventricular function was assessed by echocardiography. Patients group consisted of 34 men and 6 women. The control group consisted of 7 men and 3 women. With regard to troponin T level the results were significantly different between patients' and control group. The results of the assays in the control group were within the normal range. Patients group troponin-T mean value was 0.518 ± 2.717 ng/ml. Control groups level was 0.015 ± 0.001 ng/ml. In the patients group, CK - MB mean value was 2,17 ± 2,37 ng/ml, control group level was 0,08 ± 0,55 ng/ml. Patients group mean myoglobin level was 49,20 ± 32,29 ng/ml, in the control group level was 29,80 ± 11,41 ng/ml. The ejection fraction mean value was 30 ± 7% in patients group and 65 ± 5% in control group.

Özet

Ocak-2001 ve Haziran-2002 tarihleri arasında konjestif kalp yetmezliği nedeniyle kardiyoloji kliniğine yatırılan 40 hasta ve 10 kontrol grubunda kardiyak troponin T,CK-MB (kreatinin fosfotinaz miyokardiyal band), myoglobini prospektif olarak araştırdık. Yakında miyokard infarktüsü, yada semptomatik iskemisi olanlar çalışma dışı bırakıldı. Kardiyak troponin T,CK-MB, myoglobin immunassay metodla ölçüldü. Kalp yetmezliği derecesi New York Kalp Cemiyeti fonksiyonel sınıflandırmasına göre yapıldı. Ventriküler fonksiyon ekokardiyografi ile değerlendirildi. Hasta grubu 34 erkek, 6 kadın, kontrol grubu 7 erkek, 3 kadından ibaretti. Kardiyak troponin T düzeyleri yönünden hasta grubu ve kontrol grubu arasında anlamlı fark bulundu. Hasta grubunda ortalama kardiyak troponin T düzeyleri 0.518 ± 2.717 ng/ml, kontrol grubunda 0.015 ± 0.001 ng/ml bulundu. Hasta grubunda ortalama CK - MB düzeyleri 2,17 ± 2,37 ng/ml, kontrol grubunda 0,08 ± 0,55 ng/ml, myoglobin düzeyleri hasta grubunda ortalama 49,20 ± 32,29 ng/ml, kontrol grubunda 29,80+11,41 ng.ml bulundu. Hasta grubunda ejeksiyon fraksiyon %30 ± 7, kontrol grubunda %65 ± 5 bulundu.

🔖

Cite This Article

ÖZKAN, M., BİLGİ, C., UZUN, M., DEMİRTAŞ, E. (2002). Cardiac troponin T, CK-MB, myoglobine levels in congestive heart failure. Gülhane Tıp Dergisi, Cilt: 44 - Sayı: 4, 405–408. https://ajindex.com/articles/225808

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Del Carlo, C.H., O'Connor, CM.: Cardiac tro- ponins in congestive heart failure. Am.Heart J.Oct. 1999
  2. Narula, J., Arbustini, E., Chandiashektar, Y., Scwaiger, M. Apoptosis and the systolic dysfunc¬ tion in congestive heart failure. Cardiology Clinics. Vol.19. No:1, 2001
  3. Ho, K.K., Pinsky, J.L., Kannel, W.B.: The epi¬ demiology of heart failure. The Framingham Study. J.Am.Coll.Cardiol. 22(4 suppl.A). 6A-13A, 1993
  4. O'Connel, J.B., Bristow, M.R.: Economic impact of heart failure in the United States. Time for a different approach. J.Heart Lune Transplant. 13.5107-12, 1994
  5. CONSENSUS trial study group. Effects of enapril on mortality in severe congestive heart failure. N.Engl.J.Med. 316.1429-35, 1987
  6. SOLVD investigators. Effect of enapril on sur¬ vival in patients with reduced left ventricular ejec¬ tion fractions and congestive heart failure. N. Engl.J. Med. 325.293-302.1991, 7. Hobbs, R.E., Czerka, B.: Congestive heart fail¬ ure. Current and future strategies to decrease mortality. Postgrad.Med. 96.167,1994. 8. lannini, J.P., Spinale, F.G.: The identification of contributory mechanisms for the development and progression of congestive heart failure in animal model. J. Heart lung Transplant. 15. 1138.1996
  7. Colucci, W.S., Braunwald, £.; Pathophysiology of heart failure. Braunwald E. Editor. Heart Disease. 5th edition. Philadelphia. WB. Saunder Com. P.394-420. 1997
  8. Colucci, W. S.: Molecular and cellular mechanism of myocardial failure. Am.J.Cardiol. 80.151- 251,1997
  9. Cohn, J.N.: Structural basis for heart failure. Ventricular remodeling and its pharmalogical inhibition. Circulation. 2504-7, 1995
  10. Colucci, W.S. Apoptosis in the heart. N.Engl.J.Med. 335.1224, 1996
  11. Olivetti, G., Abbi, R., Quaini, F.: Apoptosis in the failing human heart. N.Engl.J.Med. 336.1131, 1997
  12. Narula, J., Haider, N., Virmani, R.: Apoptosis in myocites in end-stage heart failure. N. Eng. J. Med. 335.1182. 1996
  13. Gheorghiade, M., Bonow, R.O.: Chronic heart failure in the United States. A manifestation of coronary artery disease. Circulation. 97.282, 1998
  14. Adams, J.E.III, Bodor, G.S., Davilla-Romon, W.G.: Cardiac Cardiac Troponin T I. A marker with high specificity for cardiac injury. Circulation. 88.109, 1993
  15. Rottbauer, W., Greten, J., Muller, B.M. Troponin T. A diagnostic marker for myocardial and minor cardiac cell damage. Eur.Heart.J. 17(suppl.F) 3- 8, 1996
  16. Collinson, P.O.: To or not to T. That is the ques¬ tion. Clin.Chem. 43.4